The study, conducted by researchers at The Affiliated Hospital of Qingdao University and published in the Journal of Ovarian Research, systematically mined the ClinicalTrials.gov registry for ovarian cancer vaccine trials registered between 1996 and June 2026. The team extracted and analyzed data on study phase, recruitment status, enrollment size, geographic distribution, funding source, vaccine platform, combination strategy, clinical context, and endpoint selection. Their findings paint a detailed portrait of a field that has sustained momentum since the mid-1990s but has yet to translate that activity into approved therapies.

The numbers tell a striking story. The 136 unique studies collectively involved 4,180 participants. Nearly half of all trials, 48.53 percent, were Phase I studies, while 23.53 percent were Phase II and 21.32 percent were combined Phase I/II designs. Only two Phase III trials appeared in the entire registry. Completion rates were moderate, with 55.88 percent of studies finished, but transparency lagged far behind: just 22.79 percent of trials had publicly posted results. Geographically, the United States dominated the landscape, participating in 105 of the registered studies, reflecting the concentration of immunotherapy infrastructure and funding in American academic and industry centers.

On the technical side, the analysis identified five major vaccine platforms competing for dominance. Peptide and antigen vaccines, which deliver synthetic fragments of tumor-associated proteins to prime immune responses, formed the largest category. Dendritic cell vaccines, in which a patient’s immune cells are harvested, loaded with tumor antigens in the laboratory, and reinfused to act as powerful antigen-presenting scouts, represented another major approach. Whole tumor cell or lysate vaccines offer the advantage of presenting the full antigenic repertoire of a patient’s tumor, while DNA and RNA vaccines instruct the patient’s own cells to produce tumor antigens in situ. Viral and vector vaccines use engineered viruses to deliver tumor antigens and provoke strong cellular immunity. Each platform carries distinct advantages in manufacturing complexity, antigen breadth, and the type of immune response it preferentially elicits.

The mechanistic logic underlying all these platforms is the same: break immune tolerance to tumor antigens and generate durable populations of cytotoxic T lymphocytes capable of recognizing and killing ovarian cancer cells. Common antigenic targets across trials have included Wilms tumor 1, p53, and antigens associated with BRCA-mutated tumors, alongside the widely monitored biomarker CA-125. Adjuvants such as granulocyte-macrophage colony-stimulating factor have frequently been deployed to supercharge dendritic cell activation, and human leukocyte antigen typing has shaped patient eligibility in many peptide-based studies, since vaccine peptides must be presented on specific MHC molecules to be seen by T cells.

Perhaps the most important trend the analysis uncovered is a decisive shift away from single-agent vaccination toward combination strategies. Modern trials increasingly pair therapeutic vaccines with immune checkpoint inhibitors such as antibodies targeting PD-1, PD-L1, or CTLA-4, which release the molecular brakes that tumors place on T cells. Others combine vaccines with chemotherapy, exploiting the ability of certain cytotoxic drugs to promote immunogenic tumor cell death and antigen release, or with immune adjuvants that amplify the vaccine-primed response. This combinatorial logic mirrors the broader evolution of cancer immunotherapy, where vaccines are increasingly viewed as one component of a multi-pronged attack rather than a standalone cure.

The clinical context of these trials is also revealing. Most studies enrolled patients with advanced, metastatic, or recurrent ovarian cancer, populations with urgent unmet needs but also with tumors that have already evolved sophisticated immune evasion mechanisms. This creates a fundamental tension: the patients most likely to benefit from vaccination in principle, those with minimal residual disease after cytoreductive surgery and platinum-sensitive relapse, are underrepresented relative to heavily pretreated cohorts whose immune systems and tumor microenvironments are profoundly immunosuppressed. The authors argue that biomarker-guided patient selection will be essential to move the field forward, matching vaccine platforms to patients whose tumors express the right antigens and whose immune milieus remain permissive.

Endpoint selection emerged as another critical weakness. Safety and toxicity measures and immunogenicity readouts dominated the trial landscape, while progression-free survival, overall survival, quality of life, and biomarker-based outcomes were comparatively underrepresented. This skew reflects the exploratory nature of most studies but also highlights why so few vaccines have progressed: regulators and clinicians ultimately need evidence that vaccine-induced immune responses translate into longer survival and better lives, not merely stronger laboratory measurements. The immune monitoring data were particularly inconsistent. Although 92 trials, or 67.65 percent, reported immune response outcomes, only 58 trials, or 42.65 percent, specified the assay method used, and 34 trials described an immune domain without naming any assay at all. Techniques as varied as chromium-51 release assays, intracellular cytokine staining, fluorescence-activated cell sorting, immunohistochemistry, delayed-type hypersensitivity testing, and ELISPOT-based measurements appeared across the literature, making cross-trial comparisons nearly impossible.

This heterogeneity in immune-response reporting is more than a bureaucratic nuisance; it is a scientific bottleneck. Without prespecified, harmonized, vaccine-specific immune monitoring frameworks, the field cannot reliably determine which platforms, antigens, adjuvants, and combinations are genuinely superior. A promising response measured in one trial with one assay cannot be meaningfully compared to a disappointing result in another using a different technique. The study’s authors call for standardized monitoring protocols to be built into trial design from the outset, alongside clinically meaningful endpoints and immune-related response criteria such as irRC and iRECIST that account for the atypical response patterns seen with immunotherapies.

Looking ahead, the researchers outline a roadmap for the next decade of ovarian cancer vaccine development. Personalized vaccines, tailored to the unique mutation profile of each patient’s tumor, hold particular promise in a disease like ovarian cancer where homologous recombination deficiency and BRCA mutations generate abundant neoantigens. Large-scale, multicenter, randomized Phase II and III trials are urgently needed to convert three decades of immunological proof-of-principle into confirmatory clinical evidence. If the field can align biomarker-driven enrollment, combination immunotherapy, standardized immune monitoring, and survival-focused endpoints, the long-pursued dream of a therapeutic ovarian cancer vaccine may finally move from the registry pages of ClinicalTrials.gov into routine clinical practice.

Subject of Research: Clinical trial landscape of therapeutic vaccines for ovarian cancer

Article Title: Clinical landscape of therapeutic vaccines for ovarian cancer: current status, challenges, and future directions

Article References: Shan, Y., Wang, Q., Wan, W., Zhang, Y., & Chu, Y. (2026). Clinical landscape of therapeutic vaccines for ovarian cancer: current status, challenges, and future directions. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02253-0

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02253-0

Keywords: ovarian cancer, therapeutic vaccines, immunotherapy, clinical trials, dendritic cell vaccines, peptide vaccines, immune checkpoint inhibitors, combination immunotherapy, immune monitoring, personalized vaccines, ClinicalTrials.gov, translational research